This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed's Brightree Widens ReSupply Solution Usage for HME
by Zacks Equity Research
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
Looking for a Growth Stock? 3 Reasons Why Amedisys (AMED) is a Solid Choice
by Zacks Equity Research
Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.
5 Top-Ranked Stocks to Play DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
Walgreens Partners With VillageMD to Offer Primary Healthcare
by Zacks Equity Research
This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.
Buy These 5 Low Leverage Stocks to Avoid the Perils of Debt
by Zacks Equity Research
Before investing blindly in a stock exhibiting solid growth traits, one should consider the extent of its leverage in order to avoid falling into debt traps.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
Medtronic's (MDT) Study Shows Positive Results of TDD Use
by Zacks Equity Research
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid
by Zacks Equity Research
Walgreens Boots (WBA) currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.
Medtronic (MDT) Inks Value-Based Deal for Guardian Connect
by Zacks Equity Research
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
Bio-Rad's (BIO) IH-500 System Secures 510(K) From the FDA
by Zacks Equity Research
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
Intersect ENT Grows on Product Launch Amid Pricing Pressure
by Zacks Equity Research
Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.
Natus Medical to Divest Medix for Focusing on Core Business
by Zacks Equity Research
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
Medtronic's New Data for HVAD System to Boost CRHF Segment
by Zacks Equity Research
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.
Orthofix (OFIX) Reports Encouraging M6-C Disc Study Results
by Zacks Equity Research
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.
ResMed's (RMD) Brightree Unveils Analytics Platform for HME
by Zacks Equity Research
The Analytics arm, launched by ResMed (RMD) unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics
by Zacks Equity Research
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
ResMed (RMD) Rides on International Growth & Innovation
by Zacks Equity Research
We expect ResMed's (RMD) new product menu and strategies to gain traction from the sleep-disordered breathing market and further drive its near-term performance.
Inogen (INGN) Launches One G5 Portable Oxygen Concentrator
by Zacks Equity Research
Inogen's (INGN) product launch is in line with the company's strategy of providing innovative and long-term oxygen therapy to patients in need of respiratory aid.
Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake
by Zacks Equity Research
The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.
Varian Announces Halcyon's First Successful Case in Malaysia
by Zacks Equity Research
Varian's (VAR) Halcyon is much superior to traditional technologies, thanks to the speed of treatment and improved quality of patient care it offers.
Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm
by Zacks Equity Research
The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.
Walgreens Boots (WBA) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
A difficult macroeconomic environment and market challenges made the fiscal second quarter the toughest since the formation of Walgreens Boots Alliance (WBA).
Amedisys Closes Oklahoma-Based RoseRock Healthcare Buyout
by Sriparna Ghosal
The acquisition of RoseRock Healthcare aligns with Amedisys' (AMED) strategy of foraying into the hospice care market of Oklahoma.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen foothold in the multi-billion gene sequencing market.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.